Category: Psychedelic Bulletin - Page 3 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Post published:October 4, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

Post published:September 27, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Post published:September 20, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase I

Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase I

Post published:September 9, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown

Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown

Post published:August 30, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Post published:August 15, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom Large; J&J Seeks Spravato Monotherapy Approval; Canadian Study to Parse Out Role of Psychotherapy

Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom Large; J&J Seeks Spravato Monotherapy Approval; Canadian Study to Parse Out Role of Psychotherapy

Post published:July 26, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #168: California’s Psychedelic Research Bottleneck Ends Today; Neşe Devenot’s Letter to the Editor; Oregon’s Psilocybin Services a Year In; Disability and Psychedelics

Pα+ Psychedelic Bulletin #168: California’s Psychedelic Research Bottleneck Ends Today; Neşe Devenot’s Letter to the Editor; Oregon’s Psilocybin Services a Year In; Disability and Psychedelics

Post published:July 19, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated Workshop Discusses Ketamine; EMA Associates Publish Recap of Psychedelics Workshop

Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated Workshop Discusses Ketamine; EMA Associates Publish Recap of Psychedelics Workshop

Post published:July 12, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #166: Crenshaw and Musk Weigh In on MDMA; Drug Devs Clarify Trial Design In Wake of AdComm; Mini Interview: Joshua Ismin, Psylo

Pα+ Psychedelic Bulletin #166: Crenshaw and Musk Weigh In on MDMA; Drug Devs Clarify Trial Design In Wake of AdComm; Mini Interview: Joshua Ismin, Psylo

Post published:July 5, 2024
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.